Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

Shares to Robert Keith which will represent approximately 13.18 per cent. of the Company's Enlarged Share Capital. In addition, the Directors propose to issue a £1 million Convertible Loan Note to Robert Keith which can be converted at any time into a further 200,000,000 Ordinary Shares at an issue price of 0.5 pence.

The proposed issue of the 200,000,000 Subscription Shares and the Convertible Loan Note will constitute a Related Party Transaction for the purpose of AIM Rule 13 as a result of Robert Keith being a "substantial shareholder" as defined by the AIM Rules for Companies.  As at the date of this announcement, Robert Keith holds 11.67 per cent. of the Company's issued share capital.

Board Changes

As part of the Fundraising, Jerry Randall has agreed to increase his roles and responsibilities from Non-executive Chairman to become Executive Chairman.  The transition to Executive Chairman will occur at Admission. At Admission, and subject to the transition to Executive Chairman, the Board intends to grant Mr Randall share options over 3 per cent. of the issued share capital.  

In addition, the Board has decided to appoint Ali Mortazavi as Director of Corporate Strategy for the Company. Mr Mortazavi's appointment as an Executive Director will commence from Admission.  At Admission, and subject to his appointment as a Director, the Board intends to grant Mr Mortazavi share options over 5 per cent. of the issued share capital of the Company.

In addition, Dr Tony Sedgwick and Max Herrmann have agreed to step down from the Company  at Admission. In order to enable a smooth and orderly transition, Mr Herrmann has agreed to provide consultancy services to the Company for 6 months during which time, the Company will look for an appropriate replacement. Dr Sedgwick has also agreed to provide consultancy services and act as an adviser to the Company for a period of eight and a half months following the comp
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Whitehouse Laboratories is pleased to announce ... (New Jersey) Chamber of Commerce as a member. ... in the North Jersey area, offers Whitehouse Laboratories ... clients in the pharmaceutical and biotechnology areas that ... enables Whitehouse Laboratories a higher level of visibility ...
(Date:11/26/2014)... November 25, 2014 Global biostimulants ... 2019 growing at an estimated CAGR of 12.5%. ... healthy food products with least ecological impacts, farmers ... fertilizers to boost crop yield more effectively & ... that can improve the return on investments. , ...
(Date:11/26/2014)... Theravalues Corporation est fier d,annoncer le lancement de ... Hi Europe 2014 (du 2 au 4 décembre à ... la plus biodisponible actuellement sur le marché, elle ... approuvés par les règlements européens. La ... racine de curcuma ( Curcuma longa ) qui ...
(Date:11/24/2014)... 2014 Five American winners will ... Maktoum Awards for Medical Sciences", in its 8 th ... Emirates , on 15 December 2014. ... The Carter Center which won the Hamdan Award for ... numerous programs that aim to improve health and promote ...
Breaking Biology Technology:Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3Five US Winners Among Recipients of Hamdan Medical Awards 2
... Milestones, CRANBURY, N.J., Nov. 3 Amicus Therapeutics,(Nasdaq: ... third quarter of,2008. On a reported basis calculated in ... a net loss,attributable to common stockholders of $0.36 per ... three months ended September 30, 2008. As of,September 30, ...
... Nov. 3 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ... announced today that BUYINS.NET, http://www.buyins.net, is initiating ... data to October 2008. From November 2006 to ... BMOD have traded,for a total dollar value of ...
... and GUELPH, Ontario, Nov. 3 LI-COR,Biosciences ... agreement to,distribute LI-COR biotechnology products in Canada ... local presence of Mandel Scientific skilled staff, ... enhance our ability to serve,our Canadian customers," ...
Cached Biology Technology:Amicus Therapeutics Announces Third Quarter 2008 Financial Results 2Amicus Therapeutics Announces Third Quarter 2008 Financial Results 3Amicus Therapeutics Announces Third Quarter 2008 Financial Results 4Amicus Therapeutics Announces Third Quarter 2008 Financial Results 5Amicus Therapeutics Announces Third Quarter 2008 Financial Results 6Amicus Therapeutics Announces Third Quarter 2008 Financial Results 7Amicus Therapeutics Announces Third Quarter 2008 Financial Results 8Amicus Therapeutics Announces Third Quarter 2008 Financial Results 9Amicus Therapeutics Announces Third Quarter 2008 Financial Results 10Amicus Therapeutics Announces Third Quarter 2008 Financial Results 11Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report 2Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report 3Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report 4LI-COR Biosciences and Mandel Scientific Company Inc. Announce Distribution Agreement 2
(Date:11/4/2014)... University School of Medicine announced today that it ... funded by the Bill & Melinda Gates Foundation. ... Gynecology and Reproductive Sciences; and Vice Chair of ... of Medicine will pursue an innovative global health ... to Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) ...
(Date:11/4/2014)... England , November 4, 2014 ... and vertical market growth   Fuel3D , ... has closed a funding round totaling $6.4 million (£4 million). ... million) funding secured earlier this year and paves the way ... in 2015. The funding round was led by ...
(Date:11/3/2014)... -- Research and Markets has announced the addition ... and Companies" to their offering. This ... have already started to play an important role in the ... old fashioned bone marrow transplants. Role of cells in drug ... a part of medical practice. Stem cells are ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... HOUSTON, May 8, 2012 With the heart having limited ... cause of morbidity and mortality in the developed world. Research ... lecture May 15 at the University of Houston (UH). ... of Texas Southwestern Medical Center, will present "Heart Making and ...
... University scientist and designer from Africa have together created ... with insecticides for warding off mosquitoes infected with malaria, ... the continent. Though insecticide-treated nets are commonly used ... prototype garment can be worn throughout the day to ...
... Association of Pharmaceutical Scientists (AAPS) WHAT: The ... scientists from industry, government, and academia for three ... biotechnology sector of the pharmaceutical sciences. The conference ... Training Course and two AAPS Workshops, transitions into ...
Cached Biology News:New heart repair strategies discussed at UH lecture May 15 2African scientist, designer partner to fashion anti-malaria garment that wards off bugs 2
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
...
Mouse monoclonal [CAT-2] to Chloramphenicol Acetyltransferase...
Recommended fro Western blotting application...
Biology Products: